Search

Displaying results 4021 - 4030 of 4860 in total
  1. Drug

    SW033291

    go.drugbank.com/drugs/DB32765
    Experimental

    [A275473, A275474] It has been found to increase prostaglandin E2 (PGE2) and is being investigated in accelerating of hematopoietic recovery and treating type 2 diabetes mellitus.[A275473, A275474]

  2. Drug

    Nitroxoline

    go.drugbank.com/drugs/DB01422
    Experimental

    It is a hydroxyquinoline derivative unrelated to other classes of drugs.[A179251] Nitroxoline is active against bacterial gyrases.

  3. Drug

    BNC105

    go.drugbank.com/drugs/DB06313
    Investigational

  4. Drug

    Milveterol

    go.drugbank.com/drugs/DB05043
    Investigational

    GSK159797 ('797) is an inhaled, longer-acting Beta2 agonist developed for the treatment of respiratory disease such as asthma and COPD.

  5. Drug

    Azosemide

    go.drugbank.com/drugs/DB08961
    Investigational

    Azosemide is a loop diuretic used to treat hypertension, edema, and ascites.

  6. Drug

    Leptin

    go.drugbank.com/drugs/DB05098
    Investigational

    Although leptin is a circulating signal that reduces appetite, in general, obese people have an unusually high circulating concentration of leptin. These people are said to be resistant to the effects of leptin, in much the same way that...

  7. Drug

    Reslizumab

    go.drugbank.com/drugs/DB06602
    ApprovedInvestigational

    It is injected once every four weeks via intravenous infusion. Cinqair is indicated as an add-on maintenance therapy for adults with severe asthma with an eosinophilic phenotype. … It is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines. Reslizumab is marketed as Cinqaero in Europe.

  8. Drug

    Rozanolixizumab

    go.drugbank.com/drugs/DB14919
    ApprovedInvestigational

    [A260177] It is investigated for use in autoimmune and alloimmune diseases with pathologic IgG, particularly generalized myasthenia gravis. … [L47122] It was granted orphan drug designation by the FDA in 2019, by the European Medicines Agency (EMA) in April 2020, and by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in November

  9. Drug

    Galidesivir

    go.drugbank.com/drugs/DB11676
    Investigational

    [L12042] Because of its activity against other coronaviruses, it may be studied as a potential therapy for COVID-19. … [L12084] _In vitro_, it displayed broad-spectrum antiviral activity against various negative- and positive-sense RNA viruses,[A191622] including coronaviruses, filoviruses, and arenaviruses.

  10. Drug

    Sulbutiamine

    go.drugbank.com/drugs/DB13416
    Investigational

    It is highly lipophilic, allowing it to cross the blood-brain barrier more easily than other thiamine derivatives.